Longqin Hu

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer

ROS1-targeted therapies have improved outcomes in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance, CNS progression, and off-target toxicities remain important limitations. Zidesamtinib (Jideytro ® , NVL-520) is a next-generation, brain-penetrant, tropomy...

From propofol to cipepofol (Cypsedo®), a new intravenous general anesthetic approved for adults undergoing surgery

Propofol ( 1 ) remains the gold standard intravenous general anesthetic despite such drawbacks as injection pain, respiratory depression, and cardiovascular instability. The newly FDA-approved cipepofol (Cypsedo ® , 2 ) is a chiral analog incorporating a cyclopropyl ring to enhan...